The White House Says Boosters for All. Here’s What You Need to Know.
Federal officials are preparing to offer those who received Pfizer or Moderna covid vaccines a third dose in September. But the FDA and CDC are still reviewing the data for final clearance.
Lo que debes saber sobre el refuerzo de la vacuna contra covid
La administración de Biden anunció el miércoles 18 de agosto planes para ofrecer refuerzos de la vacuna contra covid-19 a todos los adultos estadounidenses a partir del próximo mes.
Pfizer CEO to Public: Just Trust Us on the Covid Booster
As pharmaceutical companies declare a need for boosters, scientists and doctors emphasize there’s no proof yet.
Novavax’s Effort to Vaccinate the World, From Zero to Not Quite Warp Speed
Novavax is a vaccine company that has never licensed a vaccine. It hopes it can still help to fight the global covid scourge, but can it get doses made worldwide?
All agree that covid vaccines are urgently needed to stop the pandemic, but simply waiving patents fails to provide technological know-how and address supply chain challenges.
‘It Didn’t Really Stick With Me’: Understanding the Rural Shrug Over Covid and Vaccines
Fort Scott, Kansas, was hit hard by the pandemic, and it no longer has a hospital. But residents remain skeptical about the impact of the coronavirus.
Pfizer’s Newest Vaccine Plant Has Persistent Mold Issues, History of Recalls
After nearly a decade’s worth of federal inspections, reprimands and corrective action plans, has Pfizer fixed the facility that will be filling vials of its covid vaccine?
Why AstraZeneca and J&J’s Vaccines, In Use Elsewhere, Are Still on Hold in America
Covid has pressed the Food and Drug Administration into its fastest vaccine reviews ever — which are still painfully slow, critics say.
With U.S. cases skyrocketing, demand for Gilead’s dark horse antiviral is only growing. Biden appointees propose potential legal tactics to tamp down the price for patients.
Why Even Presidential Pressure Might Not Get More Vaccine to Market Faster
Even invoking the widely heralded Defense Production Act to pressure drugmakers wouldn’t overcome vast obstacles.